BioStock: The innovative force behind Ultimovacs’ cancer vaccine

Promising clinical data reinforce the fact that Ultimovacs’ universal cancer vaccine UV1 has the potential to become a new line of treatment for cancer patients. The company’s broad clinical pipeline evaluating the candidate is the culmination of decades of research led by one of the pioneers in cancer immunotherapy, Professor Gustav Gaudernack. BioStock was able to get in touch with Professor Gaudernack, who is currently CSO at Ultimovacs, to learn more about his work.

Read the interview with Professor Gustav Gaudernack at biostock.se:

The innovative force behind Ultimovacs’ cancer vaccine - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/